Literature DB >> 21245974

8 Inhibitors.

.   

Abstract

Year:  2009        PMID： 21245974      PMCID： PMC2997298     

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN： 1660-3796            Impact factor:   3.747


× No keyword cloud information.
  39 in total

Review 1.  Uses of antithrombin III concentrate in congenital and acquired deficiency states.

Authors:  S Z Bucur; J H Levy; G J Despotis; B D Spiess; C D Hillyer
Journal:  Transfusion       Date:  1998-05       Impact factor: 3.157

2.  Hereditary angioedema.

Authors:  M Cicardi; A Agostoni
Journal:  N Engl J Med       Date:  1996-06-20       Impact factor: 91.245

3.  Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

Authors:  F Baudo; T M Caimi; F de Cataldo; A Ravizza; S Arlati; G Casella; D Carugo; G Palareti; C Legnani; L Ridolfi; R Rossi; A D'Angelo; L Crippa; D Giudici; G Gallioli; A Wolfler; G Calori
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

4.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.

Authors:  A T Waytes; F S Rosen; M M Frank
Journal:  N Engl J Med       Date:  1996-06-20       Impact factor: 91.245

5.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

6.  Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

Authors:  J Kienast; M Juers; C J Wiedermann; J N Hoffmann; H Ostermann; R Strauss; H-O Keinecke; B L Warren; S M Opal
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

7.  Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis.

Authors:  D Inthorn; J N Hoffmann; W H Hartl; D Mühlbayer; M Jochum
Journal:  Shock       Date:  1998-08       Impact factor: 3.454

8.  Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia.

Authors:  Johannes N Hoffmann; Brigitte Vollmar; Matthias W Laschke; Dietrich Inthorn; Jan Fertmann; Friedrich W Schildberg; Michael D Menger
Journal:  Crit Care Med       Date:  2004-04       Impact factor: 7.598

9.  Autoimmune C1 inhibitor deficiency: report of eight patients.

Authors:  M Cicardi; G Bisiani; M Cugno; P Späth; A Agostoni
Journal:  Am J Med       Date:  1993-08       Impact factor: 4.965

10.  Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

Authors:  Marcel Levi; Mitchell Levy; Mark D Williams; Ivor Douglas; Antonio Artigas; Massimo Antonelli; Duncan Wyncoll; Jonathan Janes; Frank V Booth; Dazhe Wang; David P Sundin; William L Macias
Journal:  Am J Respir Crit Care Med       Date:  2007-06-07       Impact factor: 21.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.